Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,213,909 papers from all fields of science
Search
Sign In
Create Free Account
EGFR Inhibitor ABT-414
Known as:
ABT-414
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, ABT-414 inhibits the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
R. Parrozzani
,
G. Lombardi
,
+8 authors
L. Frizziero
Therapeutic Advances in Medical Oncology
2020
Corpus ID: 219721713
Background: The aim of this study was to prospectively analyse, for the first time worldwide by in vivo clinical confocal…
Expand
2018
2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
A. Phillips
,
E. Boghaert
,
+18 authors
E. Reilly
Molecular Cancer Therapeutics
2018
Corpus ID: 4558404
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR…
Expand
Highly Cited
2018
Highly Cited
2018
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
H. Gan
,
D. Reardon
,
+17 authors
P. Kumthekar
Neuro-Oncology
2018
Corpus ID: 3804544
Background We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly…
Expand
Highly Cited
2017
Highly Cited
2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
M. J. van den Bent
,
H. Gan
,
+21 authors
D. Reardon
Cancer Chemotherapy and Pharmacology
2017
Corpus ID: 3655905
PurposePatients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene…
Expand
2017
2017
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial
A. Lassman
,
M. Bent
,
+17 authors
R. Merrell
2017
Corpus ID: 80305401
2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is…
Expand
Highly Cited
2016
Highly Cited
2016
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
A. Phillips
,
E. Boghaert
,
+10 authors
E. Reilly
Molecular Cancer Therapeutics
2016
Corpus ID: 23487020
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal…
Expand
Highly Cited
2016
Highly Cited
2016
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
D. Reardon
,
A. Lassman
,
+15 authors
H. Gan
Neuro-Oncology
2016
Corpus ID: 3733329
Background The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety…
Expand
2016
2016
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
M. Bent
,
H. Gan
,
+17 authors
D. Reardon
2016
Corpus ID: 80120734
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor…
Expand
2015
2015
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
H. Gan
,
K. Papadopoulos
,
+17 authors
D. Reardon
2015
Corpus ID: 75540068
2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR…
Expand
2014
2014
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
H. Gan
,
L. Fichtel
,
+15 authors
D. Reardon
2014
Corpus ID: 77586139
2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE